DOCSLIB.ORG

YOUNG PERSON with HAEMOPHILIA (12-15Yrs) PARTICIPANT INFORMATION SHEET

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
YOUNG PERSON with HAEMOPHILIA (12-15Yrs) PARTICIPANT INFORMATION SHEET [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] Oxford Haemophilia & Thrombosis Centre Churchill Hospital Old Road Headington Oxford OX3 7LE YOUNG PERSON WITH HAEMOPHILIA (12-15yrs) PARTICIPANT INFORMATION SHEET Study Title: Emi and Me: An Exploration of Emicizumab on the lives of people with haemophilia and inhibitors and their families Study Sponsor: Haemnet Protocol Number: Version 4 dated 26 November 2019 Principal Investigator: Simon Fletcher Co-investigators: Dr Kate Khair, Luke Pembroke Introduction This study is talking to people about what it is like to use Emicizumab (Hemlibra®) in people with haemophilia and inhibitors. We also want to find out about impact of Emicizumab use on the lives of your close family members (parents and sisters). We will get this information through talking to you all. The study will also form part of a body of work given as evidence for a PhD currently being undertaken by the Principal Investigator Please read this information carefully and talk to your mum, dad, carer or hospital haemophilia team if you have any questions. Please ask us if there is anything that is not clear or if you would like more information, our contact details are at the end of this information sheet. If you don’t want to take part that is fine. Why are we doing this study? From this study we want to find out what it is like to use Emicizumab for you and your close family members. We also want to understand what you think about your haemophilia care now and how it might be in the future. Why have I been chosen? You have been asked to take part in this study because you have haemophilia and an inhibitor and are treated with Emicizumab. Do I have to take part? 1 [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] No. It is entirely up to you. If you do decide that you would like to take part: - You will be asked to sign a form to say you agree to take part (an assent form). - You will be given this information sheet and copy of the assent form you signed to keep. We will also ask your close family members who participate in the interview to sign a consent form after they have read an information sheet designed for them. What will happen to me if I take part? The Emi and Me study will be one face-to-face interview with the researchers. If you agree to take part one of our research team will contact you and your parents/guardian to organize a convenient time to do the interview. We can do the interview at the hospital, your home or other another place that works for you. You will only take part in one interview for this study. During the interview, notes will be taken and the conversation will be recorded. The recording will then be written down and reviewed by the study research team. The interview can be done either face to face or over the internet using ZOOM®. If you tell us about any untoward experiences from using Emicizumab we will have to report these either the MHRA (Medicines and Healthcare products Regulatory Agency) or to Roche (the company that makes Emicizumab). Any information provided to the manufacturer will be fully anonymised and they will have no access to any of your personal information and we will talk with you and your parents before we send any information. How will we use information about you? We will need to use information from you for this research project. This information will include your: name initials age sex contact details current treatment o how long you have been taking Emiczumab o how frequently you are taking Emicizumab previous treatment o what factor product you were on o how frequently you took that product 2 [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] People will use this information to do the research or to check your records to make sure that the research is being done properly. People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead. We will keep all information about you safe and secure. We will write our reports in a way that no-one can work out that you took part in the study. What are your choices about how your information is used? You can stop being part of the study at any time, without giving a reason, but with your permission we will keep information about you that we already have. Where can you find out more about how your information is used? You can find out more about how we use your information at www.hra.nhs.uk/information-about-patients/ by asking one of the research team by sending an email to [email protected], or by ringing us on 01865 225316 What are the possible disadvantages, risks and possible benefits of taking part? Doing the interview may not help you directly, but it may help you and others in the future. You will receive a thank you gift voucher for participating. Taking part in the interview will mean giving up some of your time. Although we do not think that answering the questions during the interview will be upsetting, but if it is we can stop. If you want to talk to someone about it this can be arranged by your GP, who will be informed of your participation in the study, or through your haemophilia centre. What if I change my mind? If you agree to take part in the study you can stop at any time without giving any reason. If you choose to stop your doctors and nurses will look after you in exactly the same way as before. Who is organising and funding the study? The study is sponsored by Haemnet. Haemnet is a charity that supports nurses and Doctors to make sure that excellent care becomes is an everyday experience for you. The overall study is funded by Roche Products Limited (who make Emicizumab) – they will not have access to any data other than the side effect reports if these happened to you. They will also get a final report which may use anonymised quotes from interviews. The lead researcher doing the interviews is Simon Fletcher who is a specialist haemophilia nurse. 3 [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] Will my taking part in this study be kept confidential? Yes! No personal information such as your name and address will be included in the records. All audio-recordings will be transcribed word for word by a person who does this as a job – they will be unknown to you. They will have signed an agreement to keep the information safe. The paper records and recordings will be kept in locked cupboards by Haemnet. Recordings will be deleted by Haemnet once the study has been analysed. All personal information will be kept for 12 months following the end of the study, after which it will be shredded. Paper records, including the written down interviews will be kept for 15 years after the study, after which they will be shredded. Any data on computers will be password protected in line with NHS data protection procedures. You have the right to ask to see the data that has been collected about your health and if you think anything is incorrect, to have it corrected. Who has reviewed the study? Before any research goes ahead it has to be checked by a Research Ethics Committee. This is a group of people who make sure that the research is ok to do. This study has been reviewed by the London and Chelsea Ethics Committee and the reference number is 19/LO/1592. They have said that we are able to do the study. What happens if there is a problem? You should not suffer any harm or injury by being in this study. If you wish to complain or have any concerns about the way you have been treated during the study then you can talk to your parents, your haemophilia team or contact the Patient Advice and Liaison Service (PALS) at the Oxford University Hospitals NHS Foundation Trust (TEL: 01865 235855; Email: [email protected]). Will I be Informed of the results of the Study? This study will be reported in both specialist haemophilia publications and at international conferences. Each participant will receive a final report from the study team. How can I find out more about the study? If you would like any more information, please do ask any of the nurses or doctors looking after you. You can also ask question about the study with a member of the research team by calling or emailing: 4 [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] Simon Fletcher: 01865 225316 or [email protected] Dr Kate Khair: 07515 900812 or [email protected] Thank you for taking the time to read this information sheet 5 .
Load more

Recommended publications
  • Risk of Infection
    Adapted from Oxford Radcliffe Hospitals NHS Trust Cancer Care and ‘Risk of Infection, Information sheet’ Clinical Haematology Department, Cancer and Haematology Centre Haematology Service Churchill Hospital, Oxford Risk of Infection How can I help reduce healthcare associated infections? Infection control is important to the well-being of our patients and for that reason we have infection control procedures in place. Keeping your hands clean is an effective way of preventing the spread of infections. We ask that you, and anyone visiting you, use the hand rub (special gel) available at the main entrance of the hospital and at the entrance to every ward before coming in to and after leaving the ward or Important information for all patients hospital. In some situations hands may need to be washed at the sink using soap and water rather than using the hand If you require an interpreter or need a document in another rub. Staff will let you know if this is the case. language, large print, Braille or audio version please ask for assistance. www.buckshealthcare.nhs.uk Author: Haematology Leaflet code: CISS - 122 Issue date: January 2015 Version: 2 Reviewed: January 2017 Review date: January 2019 How to contact us When you have been diagnosed with a condition that affects your bone marrow or lymph glands, you are much Emergency Phone No. more at risk of infection than a member of the general public. This risk is high because it is much more difficult for Oncology/Haematology CCHU you to fight infections. Stoke Mandeville Hospital This can be a very serious situation so needs to be (Monday – Friday 9.00am – 5.00pm) acted on immediately.
    [Show full text]
  • Director of Infection Prevention and Control (DIPC) Annual Report 2017/18
    Trust Board Meeting in Public: Wednesday 12 September 2018 TB2018.84 Title Director of Infection Prevention and Control (DIPC) Annual Report 2017/18 Status For information History Previously presented at Hospital Infection Prevention and Control Committee (HIPCC) Board Lead(s) Dr Tony Berendt Key purpose Strategy Assurance Policy Performance TB2018.84 Infection Prevention & Control Annual Report 2017/18 Page 1 of 32 Oxford University Hospitals NHS Foundation Trust TB2018.84 Figure 1: A graphical summary of key events in infection control activity in 2017-18 TB2018.84 Infection Prevention & Control Annual Report 2017/18 Oxford University Hospitals NHS Foundation Trust TB2018.84 Executive Summary 1. The annual report of the Director of Infection Prevention and Control (DIPC) is a mandated report to the Board that describes the structure and key activities of the infection prevention and control (IPC) team. These activities include surveillance, outbreak investigation and management, audit, and teaching and training. 2. Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia Zero avoidable MRSA bacteraemias are permitted by national mandate. There was one unavoidable post-48 hour bacteraemia in 2017/18, and no avoidable bacteraemias. There were 3 pre-48 hour cases of MRSA bacteraemia, considered to represent the development of infection prior to hospitalisation. 3. Clostridium difficile There were 72 OUH apportioned cases identified after three days of admission for 2017/2018 against an upper set limit of 69. 4. Methicillin-sensitive Staphylococcus aureus (MSSA) Bacteraemia There were a total of 36 incidents of post-48 hour MSSA bacteraemia, a lower figure than the 41 cases last year. 5. Gram negative blood stream Infections (GNSBI) April 2017 saw the introduction of additional nationally mandated GNBSI surveillance.
    [Show full text]
  • It's Not Just a Walk in the Park !
    It’s Not Just a Walk in the Park ! BACK BY POPULAR DEMAND and this time it really isn’t a Walk in the Park! 5 mile sponsored walk supporting your Hospital Charity Sunday 5 October 2014 10.30am You decide which Ward or Department you would like to support! Oxford Radcliffe Hospitals Charitable Funds and Oxford Health Charitable Funds Support Your Hospital Charity Route Map About the event Sunday 5 October 2014 10.30am It’s Not Just A Walk In The Park is back by popular demand and this time it really isn’t a walk in the park! New for 2014 our sponsored 5 mile walk route will take in three of the four Oxford University Hospital sites and the Warneford Hospital as, after all, the event is about raising Johnmuch neededRadcliffe funds Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. for the hospitals and you will be able to specify exactly whichHorton Fund, ward General or Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield department you would like to support. Orthopaedic Centre. Horton General Hospital. John Radcliffe Hospital. It might be a ward that you or a loved one has been treated in andChurchill this will Hospital. Nuffield Orthopaedic Centre. Horton General Hospital. be your way of saying ‘thank you’ along with your family and friends. JohnIf you Radcliffe Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. are unsure of the name of the Fund you would like to support please callHorton the General Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield Fundraising Office on 01865 743444 or email at [email protected] and we will be happy to identify the correct Fund for you.
    [Show full text]
  • Annual Report 2006 2
    1. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Annual Report 2006 2. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Foreword Sir William Stubbs, Chairman The Oxford Radcliffe Hospitals NHS Trust efficient journey through their treatment. (ORH) has an international reputation for By improving our performance in this way clinical excellence and in recent years the and removing bottlenecks and duplication Trust has been able to improve its facilities we will not only enhance patients’ and efficiency to match and support this experience, we will reduce costs. This reputation. work is an obvious extension of the macro- view provided by the Strategic Review of This has taken us from being a no-star our services that we have been undertaking trust, with costs above the average, to over the past two years. a two-star trust that is among the most efficient Trusts in England. This journey has The task ahead is not a small one, meant reduced waiting times, improved but it is achievable, particularly with diagnostic equipment, new services and the extraordinary dedication and new and improved infrastructure. resourcefulness of our staff. Despite this exemplary performance we Despite the challenging times of the past and beyond, with state-of-the-art cancer are, however, in a position where the year, we have had the pleasure of seeing the services. A particularly important element county’s funding levels have for some time new Oxford Children’s Hospital and new of the Private Finance deal that has not matched the levels of demand - and West Wing nearing completion on the John made this project possible is the built- this meant that last year we received £12.4 Radcliffe site.
    [Show full text]
  • Global Atlas of Palliative Care at the End of Life
    Global Atlas of Palliative Care at the End of Life January 2014 Acknowledgements and authorship Edited by: Stephen R. Connor, PhD, Senior Fellow to the Worldwide Palliative Care Alliance (WPCA). Maria Cecilia Sepulveda Bermedo, MD, Senior Adviser Cancer Control, Chronic Diseases Prevention and Management, Chronic Diseases and Health Promotion, World Health Organization. The views expressed in this publication do not necessarily represent the decisions, policy or views of the World Health Organization. This publication was supported in part by a grant from the Open Society Foundations’ International Palliative Care Initiative. Special thanks to Mary Callaway and Dr Kathleen Foley. Contributing writers: Sharon Baxter, MSW, Canadian Hospice Palliative Care Association, Canada Samira K. Beckwith, ACSW, LCSW, FACHE, Hope Hospice, Ft Myers, FL, USA David Clark, PhD – University of Glasgow, Scotland James Cleary, MD – Pain and Policies Study Group, Madison, WI, USA Dennis Falzon, MD – WHO Global TB Program, WHO Geneva Philippe Glaziou, MD, MPhil, Dip Stat – WHO Global TB Program, WHO Geneva Peter Holliday, St. Giles Hospice, Litchfield, England Ernesto Jaramillo, MD – WHO Global TB Program, WHO Geneva Eric L. Krakauer, MD, PhD – Harvard Medical School Center for Palliative Care, Boston, MA, USA Suresh Kumar, MD – Neighborhood Network in Palliative Care, Kerala, India Diederik Lohman – Human Rights Watch, New York, USA Thomas Lynch, PhD – International Observatory for End of Life Care, Lancaster, England Paul Z. Mmbando (MBChB, MPH, DrH) Evangelical Lutheran Church, Arusha, Tanzania Claire Morris, Worldwide Palliative Care Alliance, London, England Daniela Mosoiu, MD – Hospice Casa Sperantei, Brasov, Romania Fliss Murtagh FRCP PhD MRCGP, Cicely Saunders Institute, Kings College London Roberto Wenk, MD – Programa Argentino de Medicina Paliativa Fundación, Argentina In addition, the editors would like to thank the following: All WHO collaborating centres on palliative care (see appendix for details) Ricardo X.
    [Show full text]
  • Speciality Training Infectious Diseases with Microbiology Or
    Speciality Training Infectious Diseases with Microbiology or General (Internal) Medicine Training Programme Director: Dr Bridget Atkins Trainee Representative: Dr Elham Khatamsaz Introduction ID/micro is currently a six year training programme with 12 months credit allowed if trainees obtain separate research funding during a period out of programme (OOPR). ID/GIM is a five year programme. In August 2015 a new combined infection training programme will be introduced subject to GMC approval. This will constitute 2 years of core infection training followed by either 2 years of Medical Microbiology (MM), Medical Virology (MV) or Infectious Diseases (ID) or 3 years to obtain a CCT in ID/MM or ID/MV or ID/GIM. In Oxford the programme offers training for a CCT in ID/Micro or ID/GIM. Entry is at ST3 level after achievement of Core Medical Training and MRCP (or equivalent). Trainees currently enter on the 2010 Med Micro (RCPath) and Infectious Diseases (RCP) curricula and are required to fulfil the work competencies, work placed based assessments and knowledge based assessments for both. Trainees in 2015 will be required to be on the latest curriculum which will be the new combined infection training (CIT) and relevant Higher Specialist training (HST) programme as above. Those doing general internal medicine with ID will need to fulfil the requirement of the RCP GIM curriculum. Trainees will undergo posts in microbiology/virology (in Oxford and/or Aylesbury), infection consults, infectious diseases ward, bone infection unit and GIM/ID (Oxford and/or Slough). The deanery collaborates with Wessex deanery and opportunities exist for delivery of ID in Southampton too.
    [Show full text]
  • Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors
    Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors Advanced Practice in Endocrinology Nursing With Paediatric Editors Kate Davies and Margaret F. Keil Editors Sofia Llahana Cecilia Follin School of Health Sciences, City Department of Oncology University of London Skåne University Hospital London Lund UK Sweden Christine Yedinak Ashley Grossman Northwest Pituitary Center Churchill Hospital Oregon Health and Sciences University University of Oxford Portland, OR Oxford USA UK ISBN 978-3-319-99815-2 ISBN 978-3-319-99817-6 (eBook) https://doi.org/10.1007/978-3-319-99817-6 Library of Congress Control Number: 2018968596 © Springer Nature Switzerland AG 2019, Corrected Publication 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Celebrating 13 Decades of Nurse Education 125 YEARS of NURSE EDUCATION in OXFORD
    Celebrating 13 decades of nurse education 125 YEARS OF NURSE EDUCATION IN OXFORD Welcome to the 125 Years of Nurse Education in Oxford celebration booklet ACKNOWLEDGEMENTS We wish to thank the following This booklet details the last 13 decades of nurse people or organisations for their education in Oxford and Swindon. We are grateful help in compiling this booklet: to the people who have taken time to share their experiences of nurse education. DESIGNER ■ Flora Hands, Carline Creative The training and education of health care professionals has long been a cornerstone of life in Oxford and in AUTHORS the 20th and 21st Centuries Oxford Brookes University ■ Xante Cummings has played its own vital role in working with local ■ Annie Thompson-Lynch partners to provide professional healthcare education. ■ Dr Liz Westcott Nurse training in Oxford can trace its beginnings back to 1782. Then a non-regulated training, the early THE RADCLIFFE GUILD OF NURSES – beginnings of a formal nurse education, started in 1891 PERSONAL REMINISCENCES FROM: at the Radcliffe Infirmary on Woodstock Road. ■ Rita Bayley The records, many of which we have accessed to write ■ Theresa Bentley this booklet, provide a fascinating history. Between ■ Sue Bradshaw 1921 and 1991, 7948 nurses’ names were recorded. ■ Nurse training continued at the Radcliffe Infirmary and Nicky Brennan in 1979 the John Radcliffe 2 site was opened and the ■ Anne Carter ‘The School of Nursing’ transferred to this new site. ■ Mary Campbell In the mid 1980s Malcolm Ross, then Chief Nursing ■ Mary Dickman Officer in Oxford, Pam Jones the Head of Nursing ■ June Fisher Education in Oxford entered into discussions with ■ Eileen Forbes the then Vice Chancellor, Clive Booth and senior staff ■ at Oxford Polytechnic.
    [Show full text]
  • BIOPIC: Biological Magnetic Resonance Imaging Parameters in Oropharyngeal Squamous Cell Carcinoma
    BIOPIC PROTOCOL: V0.3 21OCT2016 BIOPIC: Biological Magnetic Resonance Imaging Parameters in oropharyngeal squamous cell carcinoma Internal Reference Number / Short title: BIOPIC Ethics Ref: 17/WA/0033 IRAS Ref: 213131 Date and Version No: October 21st 2016 V0.3 Chief Investigator: Professor Fergus Gleeson Department of Radiology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Investigators: Dr Tessa Greenhalgh Clinical Research Fellow Gray Institute for Radiation Oncology & Biology University of Oxford Old Road Campus Research Building Oxford OX3 7DQ Tel: +44 (0) 1865 617330 Email: [email protected] Dr Ketan Shah Consultant in Clinical Oncology Department of Oncology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Professor Daniel Bulte Engineering Science Institute of Biomedical Engineering Old Road Campus Research Building Roosevelt Drive Oxford OX3 7DQ Email: [email protected] Protocol Version 0.3 21 October 2016 BIOPIC: Biological Magnetic Resonance Imaging Parameters in oropharyngeal squamous cell carcinoma IRAS Project number: 213131 Chief Investigator: Professor Fergus Gleeson Page 1 of 27 BIOPIC PROTOCOL: V0.3 21OCT2016 Dr Brian Burns MRI Physics Department of Oncology University of Oxford Old Road Campus Research Building Oxford OX3 7DQ Email: [email protected] Dr Nia Taylor Consultant Radiologist Department of Radiology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Dr Ketan A. Shah Consultant Pathologist Cellular Pathology John Radcliffe Hospital Headley Way Oxford OX3 9DU [email protected] Sponsor: University of Oxford Funder: Oxford Cancer Imaging Centre (OCIC) Oxfordshire Health Services Research Committee (OHSRC) Chief Investigator Signature: ........................................
    [Show full text]
  • Professor John Wass Biography
    Professor John Wass Biography John Wass is the Professor of Endocrinology at Oxford University and was Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK until 2012. His research interests include all pituitary tumours, especially acromegaly, adrenal disease, angiogenesis in endocrinology, and the genetics of osteoporosis and thyroid disease. Since 1975 he has published over 385 articles in scientific journals and as well as written many reviews and chapters in textbooks including the Oxford Textbook of Medicine and DeGroot’s Textbook of Endocrinology. He has also edited a number of different textbooks including the Oxford Textbook of Endocrinology, Clinical Endocrine Oncology and the Oxford Handbook of Endocrinology (3 editions). He was President of the European Federation of Endocrine Societies from 2001-2003 and was Chairman of the Society for Endocrinology (2006- 2009. He has also served as President of the Pituitary Society. This year he received the Lifetime Achievement Award by the Pituitary Society in the USA. He has won a number of prizes and given named lectures including the Jubilee Prize of the Society for Endocrinology. He was recently in June 2015 awarded the Distinguished Physician of the Year Award by the American Endocrine Society; the first non American to ever receive this award. Amongst his charitable activities, he is Patron of the St. Pauls Way School (with Professor Brian Cox) and he founded the Pituitary Foundation. He was Academic Vice President of the Royal College of Physicians in London, from August 2012 until August 2015. He chaired the Royal College of Physicians Working Party ‘Action on Obesity: Comprehensive Care for All’ published in January 2013, and has been involved improving services for patients with obesity.
    [Show full text]
  • Having a Blood Test Blood Tests Help Us Diagnose Your Illness and Monitor Your Treatment
    Oxford University Hospitals NHS Trust Having a blood test Blood tests help us diagnose your illness and monitor your treatment. We understand that some people find them unpleasant, and we try to treat you with care and consideration. How to find us John Radcliffe Hospital Outpatients Blue Area, Level 2 Monday 9.00am - 1.00pm Tuesday to Friday 9.00am - 4.45pm John Radcliffe Hospital Women’s Centre Outpatients Level 1 Monday and Friday 9.00am - 1.00pm Tuesday to Thursday 9.00am - 1.00pm and 1.30pm - 4.30pm Children’s Hospital Paediatric Outpatients LG1 Monday to Thursday 10.00am - 4.45pm Friday 10.00am - 12.45pm Churchill Hospital Cancer / Haematology Outpatients Level 0 Monday to Thursday 8.30am - 4.45pm Friday 8.30am - 4.00pm Horton General Hospital Pathology Laboratory Monday, Tuesday and Thursday 9.00am - 12.00 noon What to do when you arrive John Radcliffe Hospital: please take a ticket from the wall dispenser and wait for your number to be called. Women’s Centre: please take a seat outside the department and wait to be called Children’s Hospital: please go to reception Churchill Hospital: please take a ticket from the wall dispenser and wait in section A Horton General Hospital: please go to the reception desk. Please tell us if you have had any problems with blood tests before, such as fainting. While waiting we try to see everyone as quickly as possible, but delays can occur. We will inform you of any delays when you arrive. Please remember: we can only perform a blood test if you have a blood request form.
    [Show full text]
  • People's Experiences of Travelling to Hospitals in Oxford and Banbury
    People’s experiences of travelling to hospitals in Oxford and Banbury May 2017 Your voice in health and social care CONTENTS 1 Executive summary ......................................................... 3 2 Summary of findings ........................................................ 3 3 Considerations and recommendations ................................... 4 4 Travel survey at four hospital sites ...................................... 7 5 Main findings for each site ................................................ 8 6 Appendix A - John Radcliffe Hospital site .............................. 22 7 Appendix B - Horton General Hospital site ............................ 37 8 Appendix C - Churchill Hospital site .................................... 48 9 Appendix D - Nuffield Orthopaedic Centre ............................ 60 10 Appendix E – Post codes of visitors to the 4 hospital sites .......... 71 11 Appendix F – Questionnaire .............................................. 74 People’s experiences of travelling to hospitals in Oxford and Banbury May 2017 Healthwatch Oxfordshire Page 2 of 76 1 Executive summary Healthwatch Oxfordshire was commissioned by Oxfordshire Clinical Commissioning Group (OCCG) to conduct a qualitative travel experience survey of people’s experiences attending the John Radcliffe (JR) Hospital in Oxford, the Horton General Hospital (HGH) in Banbury, the Churchill Hospital, and the Nuffield Orthopaedic Centre (NOC) in Headington, Oxford. The purpose of the survey was to gain an understanding of people’s experience when travelling to and, parking at, the four Oxford University Hospitals NHS Foundation Trust (OUHFT) hospital sites. We randomly selected and spoke to 295 people over a three-week period between 8th May and 26th May 2017. 2 Summary of findings 2.1 People’s experiences Overall, people’s experience of travelling to the four hospital sites was that they would have early starts to avoid traffic, leave plenty of time to queue and park, and they were stressed by the thought of the queue to get into the John Radcliffe or Churchill sites.
    [Show full text]